Inhaled corticosteroids for chronic obstructive pulmonary disease
Authors:
- Mario CazzolaMCMario Cazzola
- Paola RoglianiPRPaola Rogliani
- Lucia NovelliLNLucia Novelli
- Maria Gabriella MateraMMMaria Gabriella Matera
- 19 October 2013
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 14 (18) , 2489-2499
Abstract
Current guidelines recommend the use of inhaled long-acting bronchodilators, inhaled corticosteroids (ICSs) and their combinations for maintenance treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD); however, it is questionable whether all COPD patients should be treated, as the long-term use of ICSs is accompanied by side effects. This article reviews the evidence about the effects of ICSs in the treatment of COPD. It mainly focuses on meta-analyses of published data and pooled analyses of primary data. It also offers an overview of pipeline developments. There is now more evidence that there are subsets of patients (mainly, frequent exacerbators with predominant chronic bronchitis and those with overlap between COPD and asthma) with a favorable response to treatment with ICSs (i.e., reduced progression of lung function loss, reduced exacerbation rate and improved health-related quality of life). Therefore, nowadays, the right question is not whether ICSs should not be used at all unless patients have concomitant asthma, but, instead, which COPD patient can benefit from a therapy with ICSs. Unfortunately, however, the number of studies that have investigated the clinical features that might predict corticosteroid response in COPD is still inadequate.Keywords
This publication has 69 references indexed in Scilit:
- Inhaled Steroids Modulate Extracellular Matrix Composition in Bronchial Biopsies of COPD Patients: A Randomized, Controlled TrialPLOS ONE, 2013
- Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysisBMJ Open, 2013
- Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trialBMJ Open, 2012
- Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodologyRespiratory Research, 2011
- Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary diseaseInternational Journal of Chronic Obstructive Pulmonary Disease, 2011
- Glucocorticosteroids: current and future directionsBritish Journal of Pharmacology, 2010
- Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespiratory Research, 2009
- One-year treatment with mometasone furoate in chronic obstructive pulmonary diseaseRespiratory Research, 2008
- Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH StudyAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Pathogenesis of COPDSeminars in Respiratory and Critical Care Medicine, 2005